Find a Clinical Trial

Showing 1 - 7 out of 7

A Modified Ketogenic, Anti‐Inflammatory Diet for Patients with High‐Grade Gliomas

A Modified Ketogenic, Anti-Inflammatory Diet for Patients with High-Grade Gliomas

Glioblastoma

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

AN2 EBO301 MAC Study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

Mycobacterial disease

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

HGB-210

A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

Sickle cell anemia

All genders

2-50

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

The ImmuneSense Study

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma – The ImmuneSense Study

Glioblastoma

All genders

18-70

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Non-Interventional Fresh Tumor Tissue

Analysis Of Cell Count, Viability, And Of Fresh Newly Diagnosed Glioblastoma Tissue

Glioblastoma

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

ANHL1931

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Lymphoma

All genders

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

NRG-BN009

Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity ≥4 Brain Metastases/Year

Brain cancer

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Modified Ketogenic, Anti-Inflammatory Diet for Patients with High-Grade Gliomas

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma – The ImmuneSense Study

Analysis Of Cell Count, Viability, And Of Fresh Newly Diagnosed Glioblastoma Tissue

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity ≥4 Brain Metastases/Year